Dr. Plakogiannis served as a professor in the Arnold & Marine Schwartz College of Pharmacy at Long Island University for over 45 years and for 25 years was the Director of the Division of Pharmaceutical sciences of the college. He was instrumental in establishing the Scientific Graduate Division (MS and Ph.D. program) and was the recipient of the TASA award for lifetime achievement at LIU, Founder Award, etc. among other prestigious awards. Dr. Plakogiannis has authored three books and more than 100 research papers with the majority in the area of Transdermal Delivery. He has mentored more than 200 MS and Ph.D. degrees, served as chair of the Academy of Pharmaceutical Sciences Basic Pharmaceutical section, and has presented his work in the USA and Europe. Dr. Plakogiannis has been a visiting professor at a number of universities, including but not limited to Kentucky University and the University of Arizona. In addition, he has served as a consultant for the pharmaceutical industry and has served as an expert witness in a number of cases. Dr. Plakogiannis holds a diploma from University of Athens (Greece), a Master degree from Ohio State University and Doctor of Philosophy from the University of Southern California.
Rodoula Plakogiannis, PharmD
Director of Clinical Research
Dr. Plakogiannis has been Associate Professor of Pharmacy Practice at the Arnold & Marie Schwartz College of Pharmacy Since 2002, and Adjunct Associate Professor at NYU Langone Medical Center since 2011. She received both her bachelor of science in pharmacy and traditional Doctor of Pharmacy degree from the Arnold & Marie Schwartz College of Pharmacy & Health Sciences. Dr. Plakogiannis completed an ASHP-accredited specialized pharmacy residency in primary care at the Bay Pines Veterans Medical Center in Tampa, FL. She is a Board Certified Pharmacotherapy Specialist, a Diplomat and Fellow of the Accreditation Council for Clinical Lipidology, and a Board Certified Clinical Lipid Specialist. She serves as one of the Board Director for the Northeastern Lipid Association and on the Accreditation Council for Clinical Lipidology's Board of Governors. She also serves as the Adverse Drug Reaction section Editor for the Journal of Pharmacy Practice. Dr. Plakogiannis has presented on a national level in addition to local seminars and has been invited to serve as a consultant at the Aegerion and Amarin Lipid Pharmaceuticals Advisory Board meetings, among others, Dr. Plakogiannis holds a Doctor of Pharmacy degree and Bachelor of Science in Pharmacy degree from Long Island University.
Nisarg Modi, Ph.D.
Director of Research & Development
Dr. Modi is a Director of R&D at Transdermal Research Pharm Laboratories, LLC. Dr. Modi completed his Bachelor of Pharmacy from Sardar Patel University, India and received M.S. and Ph.D. from the division of Pharmaceutical Science at Long Island University, Brooklyn campus. Dr. Modi has expertise in developing transdermal drug delivery systems for new chemical entities (NCE) and approved drug products through 505 (b)2 pathway with successful clinical trials. He has more than 10 years of experience in controlled release product development with a strong emphasis on multiple day transdermal drug delivery system. His work in transdermal drug delivery resulted in number of patents. Prior to joining TRPL, he volunteered at High Throughput Screening (HTS) core-facility of Memorial Sloan Kettering cancer center to determine the solubility of HTS library compounds using novel Nephelometry technique. He acquired solid dosage formulation development and manufacturing experience by working at Apex Pharmaceuticals Inc., Torrent Pharmaceutical Ltd. and Lincoln Pharmaceutical Ltd.
Marina Brovinskaya, Ph.D.
Dr. Marina Borovinskaya is a scientist with over 10 years of laboratory and research experience in pharmaceutical science field. Graduated from Long Island University with Ph.D. in Pharmaceutical Science in the area of Transdermal Drug Delivery. Before joining TRPL where she currently is holding a position of assistant director Dr. M. Borovinskaya was a part of formulation team in R&D department in Sigmapharm Laboratories which have been engaged in development, manufacturing and marketing of unique generic and brand products. Dr. M. Borovinskaya has an extensive experience in formulation design and development of unique drugs via transdermal patches.
Tammana Lather, M.S.
Tamanna Lather is working as a Research Scientist in Transdermal Research Pharm Laboratories. She received her B.S. Pharmacy and Post Graduate Diploma in Pharmaceutical Regulatory Affairs from India, M.S. Pharmaceutics with specialization in transdermal drug delivery from Arnold & Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, USA. During her masters she was selected as a scholar in Rho Chi Society. She has 7 years of research and development experience in Transdermal drug Delivery. She is co-author of patent applications. Her work in transdermal drug delivery development successfully reached to animal studies and proof of concept clinical trials. She has strong analytical and quantitative skills, her inquisitiveness and determination drives her to contribute for Transdermal Delivery Development.
Don McAfee, Ph.D.
Dr. Donald McAfee has been a scientist and manager in academia and industry for more than 40 years. His undergraduate studies were at the University of Chicago and Portland State University, and he earned his PhD at the University of Oregon School of Medicine (OHSU) in Physiology. He did his postdoctoral studies at Yale University under Dr. Paul Greengard, Nobel Laureate. During a long academic career researching ion channel pharmacology and biophysics in excitable tissues at Yale University, University of Miami, Beckman Research Institute, and the University of British Columbia, he published more than 100 scientific papers. Dr. McAfee has served as an executive in many pharmaceutical companies before founding his own company (Discovery Therapeutics) to lead the development of Neupro™, a transdermal patch-currently the second highest grossing transdermal patch in US market.